Dietary Intervention Study on Liver Health in Young Adults
Interdisciplinary Project on Liver Health With a Focus on Steatotic Changes - Pilot Project of the Radiologic Technology, Dietetics, and Biomedical Analysis Programs
This prospective randomized dietary intervention study investigates the effects of two dietary approaches on liver health in young adults over a 12-week period. Participants will be randomly assigned to either a Mediterranean diet intervention or a healthy diet based on general dietary recommendations.
Liver health will be assessed using the Ultrasound-Guided Attenuation Parameter (UGAP), together with laboratory parameters, body composition measurements, and anthropometric assessments. Measurements will be performed at baseline, after 6 weeks, and after 12 weeks.
The study aims to evaluate changes in liver fat and related metabolic parameters over time and to investigate associations between UGAP measurements, laboratory parameters, and body composition.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Daniel Trimmel, MSc
- 电话号码:4824 +43 1 606 68 77
- 邮箱:daniel.trimmel@hcw.ac.at
研究联系人备份
- 姓名:Agnes Draxler, PhD
- 电话号码:4207 +43 1 606 68 77
- 邮箱:agnes.draxler@hcw.ac.at
学习地点
-
-
Austria
-
Vienna、Austria、奥地利、1100
- 招聘中
- Hochschule Campus Wien
-
接触:
- Daniel Trimmel, MSc
- 电话号码:4824 +43 1 606 68 77
- 邮箱:daniel.trimmel@hcw.ac.at
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 20 to 30 years
- Currently enrolled as a student
- Body mass index (BMI) ≤ 39.9 kg/m²
- Willingness to attend all three study visits at baseline, Week 6, and Week 12
- Willingness to follow the assigned dietary intervention throughout the 12-week study period
- Ability to understand the study information and provide written informed consent
Exclusion Criteria:
- Known acute or chronic liver disease, including non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD)
- Acute hepatitis
- History of liver transplantation
- Excessive alcohol consumption
- Heart failure or ascites
- Electronic or implanted medical devices that contraindicate bioelectrical impedance analysis (BIA), such as a cardiac pacemaker
- Pregnancy
- Regular use of medications other than oral contraceptives, including medications with potential hepatotoxic effects
- Extreme dietary patterns or use of dietary supplements that may interfere with study outcomes
- Unwillingness to follow the assigned dietary intervention or comply with standardized measurement conditions
- Inability to provide informed consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Mediterranean Diet Intervention
Participants assigned to the Mediterranean diet intervention group receive standardized dietary education and are instructed to follow a Mediterranean dietary pattern for 12 weeks. Dietary guidance is delivered through standardized educational materials. Dietary intake and adherence are monitored using repeated 24-hour dietary recalls and food-frequency questionnaires (FFQs). |
Participants receive standardized dietary education and are instructed to follow a Mediterranean dietary pattern for 12 weeks. Core recommendations include approximately 4 tablespoons of olive oil per day, fish 2-3 times per week, legumes at least 3 times per week, and nuts or seeds at least 3 times per week. Participants are additionally encouraged to consume vegetables, fruits, whole-grain foods, and other foods characteristic of a Mediterranean dietary pattern, while limiting foods that are not characteristic of this dietary pattern. |
|
有源比较器:Control Group - General Dietary Recommendations
Participants assigned to the control group receive standardized dietary education based on general healthy eating recommendations for 12 weeks. Participants are encouraged to maintain their usual dietary habits while incorporating general healthy dietary recommendations, including the preferential use of plant-based oils instead of animal fats. The intervention does not specifically promote a Mediterranean dietary pattern. |
Participants receive standardized dietary education based on general healthy eating recommendations for 12 weeks. Participants are encouraged to maintain their usual dietary habits while incorporating general healthy dietary recommendations, including the preferential use of plant-based oils instead of animal fats. The intervention does not specifically promote a Mediterranean dietary pattern. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Ultrasound-Guided Attenuation Parameter (UGAP)
大体时间:Baseline, Week 6, and Week 12
|
Liver steatosis will be quantitatively assessed using the Ultrasound-Guided Attenuation Parameter (UGAP). Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Visual Liver Steatosis Grade
大体时间:Baseline, Week 6, and Week 12
|
Liver steatosis will be visually assessed and classified into steatosis grades 0-3. Changes in steatosis grade will be assessed over the 12-week intervention period. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Urinary Albumin Concentration
大体时间:Baseline, Week 6, and Week 12
|
Urinary albumin concentration will be assessed in spontaneous urine samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Aspartate Aminotransferase (AST)
大体时间:Baseline, Week 6, and Week 12
|
Aspartate aminotransferase (AST) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Alanine Aminotransferase (ALT)
大体时间:Baseline, Week 6, and Week 12
|
Alanine aminotransferase (ALT) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Urinary Creatinine Concentration
大体时间:Baseline, Week 6, and Week 12
|
Urinary creatinine concentration will be assessed in spontaneous urine samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Gamma-Glutamyl Transferase (GGT)
大体时间:Baseline, Week 6, and Week 12
|
Gamma-glutamyl transferase (GGT) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Alkaline Phosphatase (ALP)
大体时间:Baseline, Week 6, and Week 12
|
Alkaline phosphatase (ALP) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Bilirubin
大体时间:Baseline, Week 6, and Week 12
|
Bilirubin will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Triglycerides
大体时间:Baseline, Week 6, and Week 12
|
Triglycerides will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
大体时间:Baseline, Week 6, and Week 12
|
High-density lipoprotein cholesterol (HDL-C) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
大体时间:Baseline, Week 6, and Week 12
|
Low-density lipoprotein cholesterol (LDL-C) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in C-Reactive Protein (CRP)
大体时间:Baseline, Week 6, and Week 12
|
C-reactive protein (CRP) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Glycated Hemoglobin (HbA1c)
大体时间:Baseline, Week 6, and Week 12
|
Glycated hemoglobin (HbA1c) will be assessed in blood samples. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Body Fat Mass Assessed by Bioelectrical Impedance Analysis (BIA)
大体时间:Baseline, Week 6, and Week 12
|
Body fat mass will be assessed using bioelectrical impedance analysis (BIA). Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Skeletal Muscle Mass Assessed by Bioelectrical Impedance Analysis (BIA)
大体时间:Baseline, Week 6, and Week 12
|
Skeletal muscle mass will be assessed using bioelectrical impedance analysis (BIA). Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Total Body Water Assessed by Bioelectrical Impedance Analysis (BIA)
大体时间:Baseline, Week 6, and Week 12
|
Total body water will be assessed using bioelectrical impedance analysis (BIA). Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in DNA Damage Measured as Percentage of DNA in the Comet Tail
大体时间:Baseline, Week 6, and Week 12
|
DNA damage will be assessed using the comet assay and expressed as the percentage of DNA in the comet tail (% tail DNA). Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Malondialdehyde (MDA) Concentration
大体时间:Baseline, Week 6, and Week 12
|
Malondialdehyde (MDA) concentration will be assessed as a biomarker of oxidative stress. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Ferric Reducing Antioxidant Power (FRAP)
大体时间:Baseline, Week 6, and Week 12
|
Ferric reducing antioxidant power (FRAP) will be assessed as a measure of antioxidant capacity. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Plasma Reduced Glutathione (GSH) Concentration
大体时间:Baseline, Week 6, and Week 12
|
Plasma reduced glutathione (GSH) concentration will be assessed as a marker of redox status. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Plasma Oxidized Glutathione (GSSG) Concentration
大体时间:Baseline, Week 6, and Week 12
|
Plasma oxidized glutathione (GSSG) concentration will be assessed as a marker of redox status. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Waist Circumference
大体时间:Baseline, Week 6, and Week 12
|
Waist circumference will be measured at each study visit. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
|
Change From Baseline in Hip Circumference
大体时间:Baseline, Week 6, and Week 12
|
Hip circumference will be measured at each study visit. Change from baseline will be assessed at Week 6 and Week 12. |
Baseline, Week 6, and Week 12
|
合作者和调查者
调查人员
- 首席研究员:Agnes Draxler, PhD、Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
- 首席研究员:Daniel Trimmel, MSc、Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- HCW-LIVER-2026
- 26000979 (其他标识符:Ethics Committee of Hochschule Campus Wien)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.